Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis with polymyxin B and tigecycline- a case report
Acinetobacter baumannii nosocomial ventriculitis/meningitis, especially those due to drug-resistant strains, has substantially increased over recent years. However, limited therapeutic options exist for the Acinetobacter baumannii ventriculitis/meningitis because of the poor penetration rate of most antibiotics through the blood-brain barrier.
A 57-year-old male patient developed ventriculitis from an extensively drug-resistant strain of Acinetobacter baumannii after the decompressive craniectomy for severe traumatic brain injury. The patient was successfully treated with intraventricular and intravenous polymyxin B together with intravenous tigecycline.
The case illustrates intraventricular polymyxin B can be a therapeutic option against extensively drug-resistant Acinetobacter baumannii ventriculitis.
KeywordsAcinetobacter Baumannii Multidrug resistance Polymyxin B Ventriculitis Intraventricular therapy
External ventricular drain
Acinetobacter baumannii has emerged as a major nosocomial central nervous system infection, with mortality rates ranging from 15% to 71% for acinetobacter meningitis . Successful treatments with intraventricular/intrathecal polymyxins have been reported; however, the incidence of potential toxicity was not negligible . Here, we report a successful microbiological cure for extensively drug-resistant A. baumannii ventriculitis using intravenous and intraventricular polymyxin B together with intravenous tigecycline.
A 57-year-old male patient was transferred from another hospital to the neurosurgical intensive care unit of the Tangdu hospital. The patient had experienced a falling accident at work and then was diagnosed as having a severe traumatic brain injury. The patient underwent a decompressive craniectomy and an external ventricular drain (EVD) insertion. Eight days after the operation, the patient presented with remittent fever (peak at 39.0 °C) associated with meningeal signs and altered mental status. Empirical antimicrobial therapy was initiated with meropenem and vancomycin. Twelve days after the operation, the patient was transferred to our intensive care unit. A right frontal EVD was inserted because of bilateral hydrocephalus. Cerebrospinal fluid (CSF) analysis revealed a WBC count of 5550 × 10E6/L, with 70% polymorphonuclear leukocytes, a glucose concentration of 1.11 mmol/L, and protein levels of 3662.1 mg/L. CSF sample was cultured on columbia agar with 5% sheep blood at 35 °C in aerobic conditions for 48 h. The bacteria were identified by an automated mass spectrometry microbial identification system (VITEK MS, bioMérieux). On day 5 of the hospitalization, the patient’s CSF culture showed that the A. baumannii was susceptible only to polymyxin (MIC = 1 μg/mL) and tigecycline (MIC ≤1 μg/mL). According to the Clinical and Laboratory Standards Institute criteria, polymyxin breakpoints are susceptible (≤2 μg/ml) and resistant (≥4 μg/ml). For tigecycline, the U.S. Food Drug Administration proposed breakpoints are susceptible (≤2 μg/ml), intermediate (4 μg/ml) and resistant (8 μg/ml). A chest computed tomography scan showed lung infiltrates, which were suggestive of pneumonia. Sputum sample was cultured on Columbia agar with 5% sheep blood and MacConkey at 35 °C in aerobic conditions for 48 h. The same strain of A. baumannii was isolated from the sputum (polymyxin susceptibility was not tested). The antimicrobial therapy was changed to intraventricular (IVT) polymyxin B (50,000 U q24h), intravenous polymyxin B (450,000 U q12h), and tigecycline (50 mg q12h). The patient became afebrile 5 days after the polymyxin B and tigecycline therapy, with negative CSF cultures thereafter. However, in the treatment process, decreased CSF drainage and a contractible right ventricle were observed gradually. Ten days after the right frontal EVD placement, the right EVD was removed, and another EVD was inserted into the left lateral ventricle. Antimicrobial treatment was switched to IVT polymyxin B (25,000 U q12h), intravenous polymyxin B (475,000 U q12h), and tigecycline (50 mg q12h). A contractible left ventricle was also observed after the IVT polymyxin B administration. Next, the antimicrobial regimen was changed by stopping the IVT polymyxin B administration and continuing the intravenous polymyxin B (500,000 U q12h) and tigecycline (50 mg q12h) administration for another 14 days until the patient’s clinical conditions were stable. On day 31 of the hospitalization, the patient was discharged.
Discussion and conclusion
Over the years, Acinetobacter baumannii, which is associated with post-neurosurgical meningitis and ventriculitis, has increasingly been regarded as an important nosocomially acquired pathogen [1, 3]. Statistical data showed that 3.6–11.2% of post-neurosurgical meningitis cases are caused by A. baumannii [2, 4]. Antimicrobial-resistant A. baumannii are divided into three categories: multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR). XDR is defined as non-susceptibility to all penicillins and cephalosporins (including inhibitor combinations), fluroquinolones, aminoglycosides, and carbapenems. . In the present case, XDR A. baumannii that was susceptible only to polymyxin and tigecycline was cultured from the cerebral spinal fluid (CSF) and sputum. As a result of the poor blood-brain barrier penetration, intraventricular (IVT) therapy polymyxin B was used through the external ventricular derivation (EVD).
Emerging evidence has indicated that intrathecal (IT) or IVT colistin administration is a safe and effective treatment for XDR A. baumannii meningitis . Karaiskos et al. . summarized 36 studies and a total of 81 patients who were diagnosed with meningitis secondary to neurosurgical procedures. A total of 89% (72/81) of the cases treated with IVT/ITH colistin were eventually cured, and the median time to achieve sterilization of the CSF was 4 days. De Bonis et al. . compared the outcomes of the XDR A. baumannii ventriculomeningitis patients treated with intravenous (IV) colistin or IV plus IVT colistin. Compared with 33.3% of the cases in the IV alone group, 100% of the cases achieved CSF sterilization (a negative CSF culture result) in the IV + IVT group. The results showed that IVT colistin administration is significantly more effective than IV colistin alone . To the best of our knowledge, polymyxin B and colistin (polymyxin E) were regarded as equivalent because of their similar chemical structures and their activity spectra . However, compared to colistin, there is limited clinical data for the use of polymyxin B in ventriculitis treatment. Piparsania et al . showed successful treatment of multidrug-resistant A. baumannii neonatal meningo-ventriculitis with IVT polymyxin B in combination with IV netilmicin and polymyxin B. IVT polymyxin B (40,000 units per dose) was given alternate day for four weeks. In the present case, sterilization of CSF was detected 5 days after the IVT polymyxin B administration. Hence, we speculate that IVT polymyxin B administration could be as effective as IVT colistin administration.
In the present case, tigecycline was used intravenously. Tigecycline, which belongs to a new class of antibiotics known as the glycylcyclines , has demonstrated excellent activity against Acinetobacter strains . Pallotto et al.  showed the weak penetration of tigecycline to the CSF in a patient with ventriculo-atrial shunt infection. The average CSF concentration of tigecycline equals to 7.9% of the serum concentration. That is the reason why tigecycline is not currently recommended for Acinetobacter ventriculitis. Recently, Lauretti et al. reported a successful case of the IVT tigecycline use to treat PDR A. baumannii meningitis .
Potential toxicity is a concern associated with local administration of polymyxins. Chemical ventriculitis and meningitis which usually cause fever and altered mental state, are the most severe adverse effects reported with IVT/ITH polymyxin treatment. Karaiskos reviewed the literature and found that out of 81 patients with IVT/ITH colistin administration, chemical meningitis and chemical ventriculitis were diagnosed in 3 (3.7%) and 2 (2.4%) cases, respectively . A recent retrospective study showed that out of 9 patients with IVT colistin administration, no cases of chemical meningitis were encountered . However, to the best of our knowledge, limited reports on the adverse effects of IVT/ITH polymyxin B were published.
Therefore, we conclude that IVT and intravenous polymyxin B combined with intravenous tigecycline could be an effective therapeutic option in the treatment of XDR A. baumannii ventriculitis. Currently, IVT administration of antibiotics with favorable outcomes is widely reported. However, multicenter randomized studies are still needed to demonstrate the efficacy and safety of intraventricular administration on these patients.
Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
YQ was in charge of case reviewing and preparation of the manuscript. WG and LHL collected clinic opinions regarding on this case and drafted the manuscript. SCG and ML participated in its coordination and revised the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The study was approved by the Ethics Committee of Tangdu Hospital, Shaanxi, China.
Consent for publication
Written informed consent was obtained from the next of kin of the patient for publication of this Case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 2.Karaiskos I, Galani L, Baziaka F, Giamarellou H. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents. 41(6):499–508.Google Scholar
- 3.De Bonis P, Lofrese G, Scoppettuolo G, Spanu T, Cultrera R, Labonia M, Cavallo MA, Mangiola A, Anile C, Pompucci A. Intraventricular versus intravenous colistin for the treatment of extensively drug resistant Acinetobacter Baumannii meningitis. Eur J Neurol. 23(1):68–75.Google Scholar
- 5.Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 18(3):268–81.Google Scholar
- 6.Hoenigl M, Drescher M, Feierl G, Valentin T, Zarfel G, Seeber K, Krause R, Grisold A. Successful management of nosocomial ventriculitis and meningitis caused by extensively drug-resistant Acinetobacter baumannii in Austria. Can J Infect Dis Med Microbiol. 24(3):e88–90.Google Scholar
- 7.Cai Y, Lee W, Kwa AL. Polymyxin B versus colistin: an update. Expert Rev Anti-Infect Ther. 13(12):1481–97.Google Scholar
- 11.Pallotto C, Fiorio M, D'Avolio A, Sgrelli A, Baldelli F, Di Perri G, De Socio GV. Cerebrospinal fluid penetration of tigecycline. Scand J Infect Dis. 46(1):69–72.Google Scholar
- 12.Lauretti L, D'Alessandris QG, Fantoni M, D'Inzeo T, Fernandez E, Pallini R, Scoppettuolo G. First reported case of intraventricular tigecycline for meningitis from extremely drug-resistant Acinetobacter Baumannii. J Neurosurg. 2016;19:1–4.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.